Although pharmacogenetic testing represents one of the cornerstones of personalized medicine, the translation of genotype-based individualization of drug treatment into clinical practice is slow. The development and achievments of The pharmacogenetics Laboratory established at the Faculty of Medicine, University of Ljubljana was presented during invited lecture at the cientific meeting with international participation at CFBGC anniversary.
B.03 Paper at an international scientific conference
COBISS.SI-ID: 28544985Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized therapy. In total, 107 patients with MM, treated with gemcitabine-platinum chemotherapy, were genotyped for 11 polymorphisms in DCK, RRM1 and CDA genes. WE observed that RRM1 polymorphisms as well as haplotypes influenced treatment outcome in patients with MM treated with gemcitabine.
F.21 Development of new health/diagnostic methods/procedures
COBISS.SI-ID: 28527065We used bioinformatics approach to select marker SNPs that encompass variability within the whole RRM1 gene region. The selected SNPs could be used in pharmacogenetic studies as predictors of response to treatment with pirimidine nucleotide analogus and thus contribute to more efficient and safer treatment of cancer.
F.09 Development of a new technological process or technology
COBISS.SI-ID: 28769241